Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLBENEMID vs CO-LAV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
mild to moderate pain,fever,inflammation
Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
Probenecid: 6-12 hours (dose-dependent); colchicine: 20-30 hours (terminal) in renal impairment may prolong.
Unknown
Colchicine: primarily hepatic via CYP3A4; Probenecid: hepatic metabolism via glucuronidation and oxidation.
Codeine is metabolized via CYP2D6 to morphine (active), and via CYP3A4 to norcodeine, with further glucuronidation. Aspirin is rapidly hydrolyzed to salicylate by esterases in the gastrointestinal tract and liver; salicylate is primarily metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, with minor oxidation.
Renal: ~76% as unchanged probenecid and metabolites; biliary/fecal: minor (<5%). Colchicine: ~20% renal, ~80% fecal primarily via biliary excretion.
CO-LAV is not a recognized drug. Please check the drug name.
Probenecid: ~85-95% primarily to albumin; colchicine: ~30-50% to albumin and other proteins.
Unknown
Probenecid: 0.15-0.2 L/kg (confined to plasma and extracellular fluid); colchicine: 2-8 L/kg (wide tissue distribution, high in leukocytes).
Unknown
Probenecid: ~100% oral; colchicine: ~45% oral (range 25-50%) with significant first-pass metabolism.
Unknown
Cr Cl <50 m L/min: contraindicated. Cr Cl 50-80 m L/min: reduce dose by 50% or extend interval. Cr Cl >80 m L/min: no adjustment.
GFR 15-30 m L/min: administer 50% of standard dose every 12 hours; GFR <15 m L/min: contraindicated (except during hemodialysis, where 50% dose post-dialysis may be used).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or use with caution. Child-Pugh C: contraindicated (risk of colchicine accumulation).
Child-Pugh Class A/B: no adjustment necessary; Child-Pugh Class C: contraindicated due to risk of severe hepatotoxicity.
Not recommended for pediatric use; safety and efficacy not established.
Children >2 months: 8 mg/kg/day (based on trimethoprim) in two divided doses for UTI; for PCP prophylaxis: 150 mg/m²/day in two divided doses on 3 consecutive days per week.
Start at lowest dose (e.g., 1 tablet daily) and titrate slowly; monitor renal function and avoid in Cr Cl <50 m L/min. Consider reduced doses due to increased risk of toxicity.
Increased risk of severe adverse reactions (e.g., hyperkalemia, renal impairment); monitor renal function and potassium levels; initiate at lower doses (e.g., half the standard dose) and titrate cautiously.
No FDA boxed warning.
Codeine is contraindicated in children younger than 12 years and in children younger than 18 years following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death associated with ultra-rapid metabolism of codeine to morphine. Aspirin is associated with Reye's syndrome in children and adolescents with viral illnesses.
Severe toxicity with colchicine in renal/hepatic impairment; blood dyscrasias (probenecid); increased risk of colchicine toxicity with CYP3A4 inhibitors; avoid use with NSAIDs due to increased GI toxicity.
Respiratory depression, risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression in children with CYP2D6 ultra-rapid metabolizers; Reye's syndrome in children and adolescents with viral illnesses; increased risk of bleeding; gastrointestinal perforation and bleeding; renal impairment; hypersensitivity reactions including anaphylaxis and aspirin-sensitive asthma; drug interactions with CYP2D6 and CYP3A4 inhibitors/inducers; use in pregnancy and lactation.
Hypersensitivity to colchicine or probenecid; severe renal impairment (Cr Cl < 30 m L/min); concurrent use of P-glycoprotein or strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with colchicine; blood dyscrasias; peptic ulcer disease; acute gout flare treatment with history of uric acid renal calculi.
Hypersensitivity to codeine, aspirin, or NSAIDs; children younger than 12 years; children younger than 18 years following tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; bleeding disorders; concomitant use with MAOIs or within 14 days; third trimester of pregnancy; nursing mothers (due to aspirin); viral illness with fever in children and adolescents (risk of Reye's syndrome); concomitant use with anticoagulants (e.g., warfarin) due to bleeding risk.
Alcohol reduces efficacy and increases hyperuricemia; avoid completely. High-purine foods (e.g., red meat, organ meats, sardines, mussels) may exacerbate gout. Grapefruit juice may increase colchicine toxicity via CYP3A4 inhibition. Acidic foods (e.g., cranberries, prunes) can decrease urine p H and increase uric acid crystallization risk. Maintain adequate hydration with water.
Grapefruit juice may increase colchicine levels due to CYP3A4 inhibition; avoid concurrent consumption. High-fat meals may reduce colchicine absorption? No data for colchicine specifically; take with or without food. Alcohol may worsen gout symptoms and increase risk of pancreatitis; avoid. Lactulose effect is not dependent on food; can be taken with or without meals.
Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnormalities and fetal death, particularly in the first trimester. Probenecid should be avoided in pregnancy due to potential teratogenic effects and neonatal toxicity. Overall, use is contraindicated in pregnant women.
First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental transfer is minimal.
Colchicine is excreted into human milk with a milk-to-plasma ratio (M/P ratio) of approximately 0.9. Probenecid passes into breast milk in small amounts. Due to potential serious adverse effects in nursing infants, including gastrointestinal toxicity and bone marrow suppression, breastfeeding is not recommended during therapy.
Considered compatible with breastfeeding. M/P ratio unknown; limited excretion into breast milk expected due to high protein binding and low oral bioavailability.
No specific dose adjustment guidelines exist due to contraindication during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) may reduce efficacy, but use is not recommended.
No dose adjustment required for pregnancy. Pharmacokinetics are not significantly altered in pregnancy; standard dosing recommended.
Colbenemid is a fixed-dose combination of colchicine (0.5 mg) and probenecid (500 mg). Probenecid increases uric acid excretion by inhibiting renal tubular reabsorption; colchicine reduces gout flare inflammation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or peptic ulcer disease. Probenecid can increase serum levels of penicillins, cephalosporins, and NSAIDs. Colchicine toxicity risk increases with concurrent P-glycoprotein or CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine). Monitor for myopathy and neuropathy. May cause a false-positive urinary glucose test.
CO-LAV (colchicine/lactulose) is a fixed-dose combination used for gout flare prophylaxis but poses risks in renal impairment; colchicine dose must be reduced in CKD stage 4-5 due to narrow therapeutic index. Lactulose may cause bloating and flatulence; monitor for diarrhea-related electrolyte disturbances. Avoid concurrent use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) and P-glycoprotein inhibitors (e.g., cyclosporine) to prevent colchicine toxicity. In liver impairment, colchicine accumulation can occur; use with caution. Geriatric patients are more susceptible to colchicine neurotoxicity and myopathy.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2-3 liters of fluid daily to prevent kidney stones.,Avoid alcohol and high-purine foods (organ meats, shellfish) during therapy.,Report signs of toxicity: muscle weakness, numbness, tingling, severe diarrhea, or vomiting.,Do not take with macrolide antibiotics or antifungal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed; do not exceed the recommended dose of colchicine.,If you have kidney or liver disease, inform your doctor; dose adjustments may be needed.,Report any signs of colchicine toxicity: muscle pain, weakness, numbness, tingling, or unusual bruising/bleeding.,Lactulose may cause gas, bloating, or stomach cramps; these usually improve over time.,Stay well hydrated to prevent diarrhea-related dehydration.,Do not take any other medications, including over-the-counter, without consulting your doctor.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks with your healthcare provider.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLBENEMID vs CO-LAV, answered by our medical review team.
COLBENEMID is a Antigout Agent Combination that works by Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.. CO-LAV is a Laxative/Bowel Evacuant that works by CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLBENEMID and CO-LAV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLBENEMID is: Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.. The standard adult dose of CO-LAV is: Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLBENEMID and CO-LAV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLBENEMID is classified as Category C. Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnor. CO-LAV is classified as Category C. First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.